January 28, 2026

Nivolumab Added to Chemoradiotherapy Reduced Recurrence Risk in High-Risk Head and Neck Cancer

Adding the PD-1 inhibitor nivolumab to standard chemoradiotherapy after surgery significantly reduced recurrence rates for patients with locally advanced head and neck squamous cell carcinoma who are ...

The ASCO Post

January 28, 2026

Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer

In an interim analysis of a phase III trial (KEYNOTE-689) reported in The New England Journal of Medicine, Uppaluri et al examined the survival benefit of adding perioperative pembrolizumab to standar...

The ASCO Post

January 28, 2026

AJCC Guideline Reassessment Aims to Improve HPV-Positive Throat Cancer Staging

“The new staging will better inform clinicians and patients about a patient’s prognosis and will minimize inconsistencies in the treatments patients are offered.”

The ASCO Post

January 28, 2026

Cannabis Use Disorder and Risk of Oral Cancer

Cannabis use disorder was associated with at least a threefold increase in the risk for developing oral cancer over 5 years compared with those without cannabis use disorder, according to findings fro...

The ASCO Post

January 27, 2026

Bacterial Decolonization to Manage Acute Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma

Based on the results of a single-center phase III Chinese trial, which were published by Liao et al in JAMA Oncology, bacterial decolonization therapy with the antibiotic mupirocin may be an effective...

The ASCO Post

January 27, 2026

10-Year Incidence of Second Cancers in HPV-Positive Oropharyngeal Cancer

At 10 years, the cumulative incidence of radiation-induced second malignancies in patients receiving definitive radiation therapy for oropharyngeal cancers associated with human papillomavirus (HPV) w...

The ASCO Post

January 27, 2026

Oropharyngeal Cancer in the United States: Recent Estimates and Future Trends

A cross-sectional epidemiologic analysis found that the incidence of oropharyngeal cancer has increased among older individuals, and those with localized disease appeared to be undertreated.

The ASCO Post

January 22, 2026

Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer

The addition of the PD-1 inhibitor pembrolizumab to weekly paclitaxel, with or without the VEGFA-targeted bevacizumab, significantly improved progression-free survival and overall survival in patients...

The ASCO Post

January 22, 2026

Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women?

At the American College of Surgeons Clinical Congress 2025, a session on integrating fallopian tube removal into general surgery practice explored the need for greater awareness of offering the proced...

The ASCO Post